Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Humacyte, Inc. Common Stock

HUMA

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Last trade $0.5119
Day change -$0.0284 (-5.26%)
Day range $0.51 – $0.572
Volume 2,909,147
Market cap $150M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$150.01M
Price / earnings
—
Price / book
8.3×
Price / sales
62.61×
EV / sales
63.43×
EV / EBITDA
-1.44×

Profitability

Earnings per share
-$0.34
Return on assets
-75.47%
Return on equity
-524.6%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.68×
Current ratio
3.34×
Quick ratio
3.11×
Cash ratio
2.61×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$88.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HUMA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.03M$406K$495K$467K$753K$301K$517K$0
Cost of revenue$1.43M$1.23M$2.04M$9.08M$260K$213K$147K$0
Gross profit-$401K-$825K-$1.54M-$8.62M$493K$88K$370K$0
Selling, general and administrative$9.01M$8.03M$7.93M$7.62M$7.61M$7.81M$8.14M$7.43M
Research and development$14.1M$18.14M$19.46M$14.61M$17.27M$22.01M$15.42M$20.66M
Total operating expenses$19.73M$28.89M$27.39M$22.22M$19.99M$35.29M$23.55M$28.09M
Operating income-$20.13M-$29.71M-$28.94M-$30.84M-$19.5M-$35.2M-$23.18M-$28.09M
Interest expense-$2.37M-$2.32M-$2.27M-$3.09M-$2.61M-$2.55M-$3M-$2.51M
Income before taxes-$15.54M-$36.8M-$17.62M-$24.8M-$17.51M-$37.66M$39.14M-$20.94M
Income taxes$0$0$0$0$0$0$0$0
Net income-$15.54M-$36.8M-$17.62M-$24.8M-$17.51M-$37.66M$39.14M-$20.94M
Net income attributable to common shareholders-$15.54M-$36.8M-$17.62M-$24.8M-$17.51M-$37.66M$39.14M-$20.94M
EBITDA-$18.86M-$28.38M-$27.59M-$31.07M-$18.16M-$33.86M-$21.88M-$28.37M
Basic earnings per share-$0.06-$0.16-$0.09-$0.13-$0.11-$0.24$0.28-$0.16
Diluted earnings per share-$0.06-$0.16-$0.09-$0.13-$0.11-$0.24$0.28-$0.16

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates

Humacyte, Inc. (HUMA) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.09 loss, with a 22.22% earnings surprise. Revenue reached $1.03 million, surpassing estimates by 19.54%. However, the stock has declined 52.6% year-to-date versus the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

RenovoRx (RNXT) reported a quarterly loss of $0.07 per share, missing the consensus estimate of $0.05 loss by 40%, though revenues of $1.07 million exceeded expectations by 1.52%. The stock has gained 55.9% year-to-date, outperforming the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Humacyte, Inc. (HUMA) stock fell 12.11% on November 5, 2026, significantly outpacing the broader market decline of 4.36%. The company is scheduled to report earnings on November 10, 2026, with projected EPS of -$0.09 and revenue of $0.86 million. For the full year, Zacks projects earnings of -$0.4 per share and revenue of $4.05 million. The stock currently holds a Zacks Rank of #3 (Hold).

Zacks Investment Research

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) closed at $0.41, down 13.01% in the latest trading session, significantly underperforming the S&P 500's 1.82% decline. The stock has fallen 6.58% over the past month while the Medical sector gained 5.28%. Upcoming earnings are expected to show an EPS of -$0.09 with revenue of $0.86 million, though full-year projections show mixed results. The company holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Humacyte, Inc. (HUMA) rose 1.28% to $0.41 in the latest session, outperforming the S&P 500's 0.58% gain. However, the stock has declined 30.34% over the past month, significantly underperforming the Medical sector's 3.5% gain. The company holds a Zacks Rank #3 (Hold) with projected quarterly EPS of -$0.09 and revenue of $0.86 million, though annual estimates show mixed signals with declining earnings but nearly doubled revenue.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.